There may be light at the end of the tunnel regarding Medicare payments for studies with the PET radioisotope fluorodeoxyglucose (FDG). The Health Care Financing Administration last month informed members of the Institute for Clinical PET that the agency
There may be light at the end of the tunnel regarding Medicare payments for studies with the PET radioisotope fluorodeoxyglucose (FDG). The Health Care Financing Administration last month informed members of the Institute for Clinical PET that the agency is preparing to make a positive recommendation covering Medicare reimbursement for the use of FDG in lung cancer studies.
HCFA's move would be the first time that the agency has allowed Medicare payment for FDG studies, and it could help spark the still-developing market for clinical PET. It is also expected to increase demand for high-energy imaging on conventional gamma cameras, such as with coincidence detection techniques.
Sources close to the ICP indicate that HCFA has agreed to forward its recommendation in the next 60 to 90 days to intermediary insurance companies that actually make payments to Medicare beneficiaries. The level of reimbursement and whether it will be set at different levels for conventional PET and coincidence detection exams are still unknown.
In another bit of good news for PET advocates, legislation that would strip the Food and Drug Administration of its power to regulate cyclotron-produced radioisotopes passed the Senate in September and appeared headed for victory in the House of Representatives as well. The bill is part of legislation to reform the FDA, and it would mandate that cyclotron-produced radioisotopes be regulated under state practice of pharmacy rules.
A Victory for Radiology: New CMS Proposal Would Provide Coverage of CT Colonography in 2025
July 12th 2024In newly issued proposals addressing changes to coverage for Medicare services in 2025, the Centers for Medicare and Medicaid Services (CMS) announced its intent to provide coverage of computed tomography colonography (CTC) for Medicare beneficiaries in 2025.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
ACR Collaborative Model Leads to 35 Percent Improvement with Mammography Positioning Criteria
July 1st 2024Noting significant variation with facilities for achieving passing criteria for mammography positioning, researchers found that structured interventions, ranging from weekly auditing of images taken by technologists to mechanisms for feedback from radiologists to technologists, led to significant improvements in a multicenter study.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.